

Context

- On 14 August 2024, the WHO declared mpox a Public Health Emergency of International Concern due to the rapid spread of subclade Ib in the eastern Democratic Republic of the Congo (DRC) and five neighbouring countries that had not previously been affected by mpox.
- The mpox Global Strategic Preparedness Response Plan highlighted the urgent need for proactive measures and research to address critical knowledge gaps.
- We had previously maintained [a living evidence profile of the best-available evidence related to the mpox outbreak](#) with 11 versions produced between May 2022 and October 2022 (at which time no further updates were deemed necessary).
- Version 12 was published in [August 2024](#), which was requested to solely focus on published evidence syntheses and single studies about clade I (including Ia and Ib) given the global spread.
- To bridge the previous versions from 2022 with the latest developments related to the mpox outbreak in 2024, we identified evidence syntheses related to mpox published between 2019 to 5 November 2024 and any new single studies on clade I (including Ia and Ib) that were published since version 12.
- After removing any duplicate evidence documents, we included a total of 172 evidence documents (evidence syntheses and single studies focused on clade I), which includes 22 identified from version 12 and 150 newly identified documents.
- Given the volume of available research evidence, this update summarizes only the key findings from high-quality evidence syntheses across all clades and newly identified single studies that specifically focus on clade I (Ia and Ib).

Question

- What is the best-available evidence related to the mpox outbreak?

High-level summary of key findings

- This LEP includes evidence documents from the previous version, giving a total count of 172 evidence documents (140 evidence syntheses, 31 single studies, and one set slides from a global conference).

Living evidence profile

Best-available evidence related to the mpox outbreak

4 December 2024

[MHF product code: LEP 6.13b]

Box 1: Evidence and other types of information

+ Global evidence drawn upon



Evidence syntheses selected based on relevance, quality, and recency of search

+ Forms of domestic evidence used (🇨🇦 = Canadian)



Evaluation



Data analytics

* Additional notable features

Prepared in the equivalent of three-business days using an 'all hands-on deck' approach

- We appraised the quality of each evidence synthesis using the AMSTAR tool, categorizing 24 as high-quality, 75 as medium-quality, and 41 as low-quality.
- Our findings focus on new insights from 24 high-quality evidence syntheses related to mpox.
- We also summarize the key findings from seven new single studies focused on clade Ia and/or Ib that we identified since the publication of version 12 in August 2024.
- Most of the evidence documents did not specify the clades or subclades; however, we report them where specified by the evidence.
- Genomic studies provided insights into the recent evolution and spread of mpox, including the circulation of subclade Ia and Ib in Central Africa.
- Subclade Ib appears to have a longer incubation period and slower transmission dynamics than subclade IIb.
- Transmission patterns have shifted from pre- to post-2022, where there has been an increase in human-to-human transmission since 2022.
- Most of the reported mpox global outbreaks have primarily affected men who have sex with men (MSM) and there are growing concerns on the impact of mpox on people living with HIV, women, pregnant people, and children.
- The use of vaccines was predominately described in the available research evidence for the prevention and control of mpox.
- Symptoms of mpox have become more varied over time, although the prevalence of lesions and rashes remains consistent.
- We identified limited evidence about the diagnosis, prognosis, and treatment of mpox; however, there are randomized controlled trials on underway in Canada and the United Kingdom on the effectiveness and safety of tecovirimat.

Box 1: Approach and supporting materials

At the beginning of each living evidence profile and throughout its development, we engage a subject matter expert and citizen partners, who help us to scope the question and ensure relevant context is taken into account in the summary of the evidence.

We identified evidence addressing the question by searching PubMed. Updated searches were conducted on 4 September 2024, 1 October 2024, and 5 November 2024 to identify any evidence syntheses about mpox, as well as any single studies focused on clade I since the last version. The search strategies used are included in Appendix 1. In contrast to synthesis methods that provide an in-depth understanding of the evidence, this profile focuses on providing an overview and key insights from relevant documents.

We appraised the methodological quality of evidence syntheses that were deemed to be highly relevant using the first version of the [AMSTAR](#) tool. AMSTAR rates overall quality on a scale of 0 to 11, where 11/11 represents a review of the highest quality, medium-quality evidence syntheses are those with scores between four and seven, and low-quality evidence syntheses are those with scores less than four. The AMSTAR tool was developed to assess reviews focused on clinical interventions, so not all criteria apply to evidence syntheses pertaining to delivery, financial or governance arrangements within health systems or implementation strategies.

Note that the timing, frequency, and scope of future updates of this LEP will be determined in collaboration with the requestor.

A separate appendix document includes:

- 1) methodological details (Appendix 1)
- 2) overview of the included evidence syntheses and single studies (Appendix 2a-c)
- 3) Key findings from the high-quality evidence syntheses and new single studies (Appendix 3)
- 4) details about each identified high-quality synthesis (Appendix 4)
- 5) details about each identified single study (Appendix 5)
- 6) categorization of the medium and low-quality syntheses (Appendices 6, 7)
- 7) documents that were excluded in the final stages of review (Appendix 8)

This update to the living evidence profile was prepared in the equivalent of three day of a 'full court press' by all involved staff.

Framework to organize what we looked for

- Biology
 - Clade I
 - Subclade Ia
 - Subclade Ib
 - Clade II
 - Subclade IIa
 - Subclade IIb
- Epidemiology
 - Transmissibility
 - Geographic spread
 - Protective immunity
- High-risk populations
 - 2SLGBTQI+
 - Children
 - Pregnant people
 - People who are immunocompromised
 - Healthcare workers
 - Other
- Prevention and control
 - Information and education (e.g., including risk communication)
 - Non-pharmaceutical measures to prevent infection
 - Non-pharmaceutical measures to control the spread of infections
 - Pharmaceutical measures used as part of public health strategies
 - Strategies grounded in behavioural science
 - Surveillance and reporting
- Diagnosis
- Clinical presentation
 - Symptom onset and duration
 - Complications
 - Variability in clinical presentation
- Prognosis (e.g., clinical severity, including morbidity and mortality)
- Treatment

What we found

We identified a total of 140 evidence syntheses on mpox that were published between 2019 to 5 November 2024. We appraised the quality of each evidence synthesis (using the AMSTAR tool), categorizing 24 as high-quality, 75 as medium-quality, and 41 as low-quality. Additionally, since version 12 published in August 2024, we identified seven new single studies specifically focused on clade I (including Ia and Ib). This LEP also includes evidence documents from the previous version, giving a total count of 172 evidence documents (140 evidence syntheses, 31 single studies, and one slide deck from a global conference).(1-172)

Given the volume of available evidence, we incorporate new insights from the 24 high-quality evidence syntheses across all clades and the seven single studies that were newly identified on clade I to the key findings from the previous version. Details of each identified high-quality evidence synthesis and single study are available in Appendices 4 and 5.

The high-level categorization of the medium and low-quality evidence syntheses are in Appendices 6a and 6b (and the full categorization available in Appendix 7).

Coverage by and gaps in existing evidence syntheses and domestic evidence

The identified high-quality evidence syntheses and single studies provide both historical and current insights of mpox in terms of its biology, epidemiology, high-risk populations, prevention and control, diagnosis, clinical presentation, prognosis, and treatment. Most of the evidence documents did not specify the clades or subclades; however, we report them where specified by the evidence. There appears to be emerging insights on genomics and transmission about subclades Ia and Ib in recent single studies. Further, there are additional studies about high-risk populations such as people living with HIV, women, and children. We also reported on any relevant information to Canada, such as the upcoming randomized controlled trial (PLATINUM-CAN) in Canada to assess the effectiveness and safety of tecovirimat.

There are still gaps in the evidence on mpox. We identified limited information about prevention and control, diagnosis, prognosis, and treatment that differentiated the impacts based on clades and subclades. There continues to be a lack of evidence on the long-term health impacts of mpox infections and the socio-economic consequences of outbreaks in affected communities.

Key findings from included high-quality evidence syntheses and single studies

Biology

Emerging research has highlighted the recent gaps in understanding the biology of mpox and its subclades. A scoping review (pre-print) focusing on clades I and II identified a lack of knowledge related to how the virus alters the host's physiology and biochemistry.(8)

Clade I

Clade I monkeypox virus, historically prevalent in Central Africa, exhibits distinct biological characteristics that set it apart from other clades.(124) Genomic analysis has revealed that clade I possesses certain genes, such as a homolog of the vaccinia virus complement control protein, which are absent in the West African clade (clade II). This may contribute to its potential for increased virulence, however there is still uncertainty.(8)

A new 2024 global analysis of 10,670 sequences collected from 65 countries (including Canada) revealed that most of the genetic data originated from outbreaks between 2022 and 2024.(121) The study found clade I continues to circulate mainly in Central Africa.

Biologically, the incubation period of mpox can vary between clades. Some studies suggest that clade I may have a longer incubation period compared to other clades, however the current evidence is not clear.(124) However, recent research indicates that the differences may not be statistically significant. A comprehensive analysis of the 2022 global outbreak and historical data estimated a pooled mean incubation period of 8.1 days (95% CI: 7.0–9.2 days) across all clades. Clade I infections were characterized by a mean of 7.3 days (95% CI: 5.0–10.2 days), whereas clade II infections showed a mean of 8.9 days (95% CI: 6.6–11.7 days). However, these differences were not statistically clear and could be due to sampling variability.(128)

DNA extracted from a single lesion is sufficient to conduct complete genome sequencing of the monkeypox virus strain, allowing for accurate determination of the virus's genetic lineage and potential geographic origin.(51) This genetic analysis capability enhances our understanding of the virus's biology.

Epidemiology

Unspecified clade

The identified evidence syntheses and single studies describe transmission patterns and potential reservoirs for mpox. An evidence synthesis (including three Canadian studies) reported a shift in mpox transmission patterns from pre- to post-2022.(59) The authors reported that prior to 2022, most of the reported cases were caused by animal-to-human transmission, but almost all reported cases since 2022 had a history of human contact, particularly sexual transmission. Another evidence synthesis reported that the 2022 mpox outbreak also saw higher average ages and comorbidity rates than previous years, emphasizing the need for global cooperation to address the spread and impact.(40) In terms of reservoirs, two evidence syntheses indicated that skin lesions have high viral loads, which could contribute to high infectivity and drive rapid transmission, especially during direct skin-to-skin contact through close physical proximity.(132;133)

Clade I

Clade I monkeypox virus has historically been known for its circulation in southern, forested regions of African countries in the Congo basin, primarily the DRC and Cameroon.(155) The geographic spread of clade I appears to be expanding, with travel-related infections originating largely in Ghana, Côte d'Ivoire, the Democratic Republic of the Congo, and spreading to other countries. Historically, clade I transmission has been primarily zoonotic, with high exposure to rodents (91%) and non-human primates (77%).(36;37) However, recent evidence indicates evolving transmission patterns.(74) A cluster of clade I mpox infections in March 2023 in the Democratic Republic of the Congo was reported to be transmitted through sexual contact, a route previously associated only with clade II.(74)

Subclade Ia and Ib

Genomic studies provided insights into the recent evolution and spread of mpox clades Ia and Ib. Regarding subclade Ia, a study reported that multiple strains of mpox have circulated in the Republic of the Congo during the 2024 outbreak after analysing samples collected from Brazzaville, Point-Noire, Likouala, Cuvette-Centrale, and Plateaux, which were likely introduced through both cross-border human-to-human transmission and direct zoonotic events. The study also indicated that there is evidence of local spread in previously unaffected areas.(171)

For subclade Ib, three new studies from the Democratic Republic of the Congo added insights to understanding transmission modes and disease severity. For example,, clade Ib been linked to sustained human-to--human transmission, including but not limited to sexual transmission.(19;76;162) One of the studies also reported that in addition to subclade Ib being present in the Democratic Republic of the Congo, there appears to be patterns associated with subclade Ia, which suggests multiple zoonotic introductions.(76) These new findings align with studies previously reported (142;152) and with a newly published evidence synthesis on human-to-human transmission patterns.(59)

Clade II

A global genomic analysis reported that clade IIb appears to have shown more cases of human-to-human transmission across different geographical regions spread than clade I.(121) Clade IIb may have faster transmission dynamics compared to clade I and subclade Ib.(104)

High-risk populations

Unspecified clade

Since 2022, most of the mpox outbreaks have primarily affected MSM.(4;59;95) There have also been reported and confirmed cases of mpox among people living with HIV, women, and children. Growing concerns have emerged regarding the impact of mpox among women and children in endemic regions.(140) In pregnant people, moderate to severe monkeypox virus infections have been associated with high rates of miscarriage, intrauterine fetal death, and perinatal loss, highlighting the need for maternal and fetal monitoring according to the seven reported cases in the

synthesis.(28) Among the cases, two were reported to have suspected vertical transmission where one of the fetuses showed hydrops (i.e., severe swelling in the body). However, the authors indicated that the risk of congenital mpox has not been established. As reported in the previous living evidence profile, outbreaks in Central African Republic have occurred since 2018, which primarily affected forested regions and younger populations, with children under 16 being particularly vulnerable.(16) Similarly, in the Democratic Republic of the Congo, 60% of cases were found in children under 14 years of age.(37)

Subclade Ia and Ib

Subclade Ia appears to primarily affect children under the age of 15, who make up more than 90% of cases.(152) Specific to the subclade Ib findings in the Democratic Republic of the Congo, most cases appear to be mainly in adults (85%). Of these cases, 52% are female, and 15% are children under 15. The HIV co-infection rate among those with known status was 7%, though it is important to note that the baseline HIV prevalence in the studied population is not specified in the available data, nor is the number of people with viral suppression from treatment as compared to no treatment.(152)

Prevention and control

Unspecified clade

The use of vaccines was predominately described in the available research evidence for the prevention and control of mpox. An evidence synthesis described that the Another evidence synthesis reported that there is limited evidence on the effectiveness of contact-tracing, sexual behaviour modification and asymptomatic testing to prevent the transmission of mpox.(123) For example, the utility of asymptomatic testing was limited, however there may be some utility to raise awareness and increase case finding during an outbreak. An evidence synthesis (literature last searched in 2022) noted the use of smallpox vaccine (MVA-BN vaccine), vaccinia immunoglobulin, and antiviral medicines can be used to prevent spreading of mpox (all clades).(8) The synthesis also notes that some existing antiviral medicines used to treat orthopox virus infection may be used alone or in combination with vaccines to treat mpox. These include tecovirimat and brincidofovir, which have been used in the U.K. to reduce viral titres in patients with mpox (clade not specified). In addition, the synthesis highlights the importance of personal protective equipment, including masks, goggles, gloves, or specific impervious long-sleeved gowns in clinical settings.(8)

There are variations in vaccine acceptance across different regions of the world. An evidence synthesis reported higher prevalence of mpox vaccination acceptance in Asian and African countries compared to North America and Europe among healthcare workers.(108) Another evidence synthesis reported a higher acceptance in European countries compared to Asian countries. The sub-analysis of the study revealed that vaccine acceptance was highest among the LGBTI communities, followed by healthcare workers and the general population.(161)

Clade II

A 2024 systematic review reported that the MVA-BN vaccine is highly effective in preventing mpox clade IIb, with vaccine effectiveness (VE) estimated at 76% for one dose (95% CI: 64-88%) from 12 studies, and 82% (95% CI: 72-92%) for two doses from six studies. Additionally, the vaccine prevented hospitalization with an effectiveness of 67% (95% CI: 55-78%), Post-exposure prophylaxis (PEP) shows limited effectiveness at 20% (95% CI: 24-65%) from seven studies, which was influenced by timing and exposure conditions.(126)

Diagnosis

There appear to be efforts to improve the diagnosis of mpox, including the development and availability of diagnostic kits. Historically, a scoping review from 2022 (pre-print) found that there was a lack of mpox virus-specific rapid diagnostic kits, but rather the available kits at that time were adapted from other viruses such as smallpox or other orthopox viruses.(8) Since then, , a recent 2024 survey indicated that European Centres in the European Union have

showed a high capability for confirming cases by PCR and to identify clades and/or subclades.(82). Further, a previously reported single study noted that researchers validated a new real-time PCR assay (14-16) that can successfully detect suspected mpox cases of clade Ib.(142)

Clinical presentation

Unspecified clade

Symptoms of mpox have become more varied over time between 1970 to 2023, although the prevalence of lesions and rashes remain consistent.(151) According to the findings presented at an international conference convened on 29 and 30 August 2024 by the World Health Organization,(152) the face is the primary rash site in 82% of cases, often with a centrifugal distribution and over 100 lesions in 51% of cases. High rates of lymphadenopathy (80%, mainly submaxillary and cervical) and febrile prodrome (80%) are common. Further, an evidence synthesis reported that oral lesions were found to be among the first clinical signs of mpox, and ulcers on the dorsal surface of the tongue and lips were the most commonly affected areas.(12) Another evidence synthesis described the clinical presentation of mpox as including a prodromal period with fever, headache, night sweats, myalgia, coryzal illness (i.e., common cold), and peripheral lymphadenopathy, and after one to two days, the presentation of lesions in the mucosal surfaces and skin.(8)

Two evidence syntheses reported that the mpox virus can lead to eye-related symptoms and complications such as conjunctivitis, eyelid lesions, and in some severe cases, corneal opacity that can cause blindness. These symptoms were found to be more common in Africa compared to other regions, highlighting the need for healthcare workers in endemic regions to prioritize early detection and treatment.(49;136) Other reported symptoms in both clades include otolaryngologic (i.e., headache, sore throat, cough, cervical lymphadenopathy) and neurological and psychiatric presentations (i.e., encephalitis, confusion, seizures) symptoms.(11;143)

Prognosis

Historically, an evidence synthesis reported that the 2022 mpox outbreak was spreading quickly with 35% of cases resulting in hospitalization and 5% fatality rate of both clades.(15) Recent surveillance data from a WHO conference presentation describes global mortality rates between 5–10% for clade Ia, 0.7% for clade Ib, 0% for clade IIa, and 3–5% for clade IIb.(152)

Clade I

Related to high-risk populations, an evidence synthesis reported that pediatric case fatality rate reached 11% (95% CI 4–20) according to a pooled analysis of studies spanning from 1972 to 2023 in 16 countries. Higher fatality rates were observed in clade I compared to clade IIa and IIb in endemic regions.(137) One medium quality evidence synthesis reporting on historic data (between 1970 and 2014) noted that the median age for mpox infection in the DRC was under 16.(15) A single study of clade I infections (from 2001 until 2021) in the Central African Republic similarly found particularly high rates of case fatality among children and those in close contact with wildlife.(16)

Treatment

In the context of mpox, an evidence synthesis with 18 uncontrolled studies reported that individuals were treated with tecovirimat (n= 61), cidofovir (n= 7), and brincidofovir (n= 3), where 83% individuals reported to have complete resolution of symptoms. (145) A randomized, placebo-controlled clinical trial (RCT) called PLATINUM-CAN is being conducted in Canada to assess tecovirimat in MPXV infection. It is a sister study to the PLATINUM-UK at Oxford University, where they aim to combine the results of both clinical trials.

A Cochrane review of therapeutics for treating mpox found no evidence from RCTs regarding the efficacy and safety of treatments. However, tecovirimat appears to not cause serious safety concerns (based on very low-certainty evidence), while brincidofovir may cause liver injury.(47) A recent high-quality evidence synthesis produced in 2022 noted that recovery can be supported by antiviral medications such as tecovirimat and brincidofovir, rehydration therapy and nutritional supports.(8) A recent single study reported on the use of oral tecovirimat (600 mg twice daily) for treating patients with mpox and reported that by day 14 most individuals had been discharged and were confirmed negative using real-time PCR detecting viral DNA from blood samples or lesion swabs. The study reported that the median time from the initiation of treatment until the absence of active lesions was five days.(107)

Next steps based on the identified evidence

We identified several knowledge gaps that were highlighted in the evidence that we included in this rapid evidence profile that could be explored to improve our understanding and management of mpox outbreaks. Generally, there needs to be a focus on generating high-quality evidence syntheses and studies that specify and study the impact of the clades and subclades, particularly on the biology, impact on high-risk populations, prevention and control strategies such as information, education and non-pharmaceutical measures, and prognosis for both general and high-risk populations.

- Continue supporting the early detection of and timely response to outbreaks (clade I and clade II), including using standardized reporting protocols, leveraging genomic surveillance to track the evolution and transmission dynamics of the virus, and strengthen surveillance systems
 - Continue to leverage genomic surveillance to track the evolution of the virus.
 - Implement more active epidemiologic surveillance to better understand the true incidence of mpox.
- Generate evidence related to potential treatments (e.g., randomized controlled trials), investigating the long-term health outcomes for survivors of mpox infections, studying the socio-economic impacts of mpox outbreaks on affected communities, examining how environmental factors that influence mpox transmission and persistence (e.g., describing a One Health approach, virus survival on environmental conditions, investigating the roles of fomites or through air transmission), and exploring effective non-pharmaceutical measures and education (including the use of behavioural science)
- Determine any differentiating diagnosis and prognosis of the mpox clades and subclades

References

1. Abdelaal A, Reda A, Hassan AR, et al. Monkeypox-Associated Manifestations and Complications Involving the Eye: A Systematic Review and Meta-Analysis of Previous and Current Outbreaks. *Asia Pac J Ophthalmol (Phila)* 2023; **12**(3): 326-37.
2. Abdullah K, Hussain J, Chan E, et al. A Review of Evidence Related to the Zoonotic Characteristics of the Monkeypox Virus. *Open Forum Infect Dis* 2024; **11**(Suppl 2): S146-s55.
3. Abu-Hammad O, Abu-Hammad A, Jaber AR, Dar-Odeh N. Factors associated with geographic variations in the 2022 monkeypox outbreak; A systematic review. *New Microbes New Infect* 2023; **51**: 101078.
4. Abu-Hammad O, Arabiat D, Althagafi N, et al. Sexually transmitted diseases and HIV co-infection among adult male patients in the 2022 monkeypox outbreak: a systematic review and meta-analysis. *Dermatol Reports* 2024; **16**(2): 9860.
5. Akter F, Hasan TB, Alam F, et al. Effect of prior immunisation with smallpox vaccine for protection against human Mpox: A systematic review. *Rev Med Virol* 2023; **33**(4): e2444.
6. Allan-Blitz LT, Carragher K, Sukhija-Cohen A, et al. Laboratory validation and clinical performance of a saliva-based test for monkeypox virus. *Journal of Medical Virology* 2023; **95**(1): e28191.
7. Amzat J, Kanmodi KK, Aminu K, Egbedina EA. School-based interventions on Mpox: A scoping review. *Health Sci Rep* 2023; **6**(6): e1334.
8. Anjorin A-AA, Odetokun IA, Ashaka OS, et al. Critical Appraisal of Mpox (Monkeypox) in Africa using Scoping and Systematic Reviews: Epidemiology, Biochemistry, Phylogeny, Pathogenesis, Clinical Features, Diagnosis, Treatment, Biosecurity and One-Health. Research Square; 2023.
9. Ardila CM, Arrubla-Escobar DE, Vivares-Builes AM. Oral lesions in patients with human monkeypox: A systematic scoping review. *J Oral Pathol Med* 2023; **52**(6): 459-67.
10. Azzam A, Khaled H, Salem H, et al. The impact of immunosuppression on the mortality and hospitalization of Monkeypox: a systematic review and meta-analysis of the 2022 outbreak. *Virol J* 2024; **21**(1): 130.
11. Badenoch JB, Conti I, Rengasamy ER, et al. Neurological and psychiatric presentations associated with human monkeypox virus infection: A systematic review and meta-analysis. *EClinicalMedicine* 2022; **52**: 101644.
12. Bagde H, Dhopte A, Bukhary F, et al. Monkeypox and oral lesions associated with its occurrence: a systematic review and meta-analysis. *F1000Res* 2023; **12**: 964.
13. Barboza JJ, León-Figueroa DA, Saldaña-Cumpa HM, et al. Virus Identification for Monkeypox in Human Seminal Fluid Samples: A Systematic Review. *Trop Med Infect Dis* 2023; **8**(3).
14. Beer EM, Rao VB. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. *PLoS Negl Trop Dis* 2019; **13**(10): e0007791.
15. Benites-Zapata VA, Ulloque-Badaracco JR, Alarcon-Braga EA, et al. Clinical features, hospitalisation and deaths associated with monkeypox: a systematic review and meta-analysis. *Ann Clin Microbiol Antimicrob* 2022; **21**(1): 36.
16. Besombes C, Mbrenge F, Schaeffer L, et al. National Monkeypox Surveillance, Central African Republic, 2001–2021. *Emerging Infectious Diseases* 2022; **28**(12): 2435.
17. Bournier J, Garcia-Gallo E, Mbrenge F, et al. Challenges in clinical diagnosis of Clade I Mpox: Highlighting the need for enhanced diagnostic approaches. *PLOS Neglected Tropical Diseases* 2024; **18**(6): e0012087.
18. Bragazzi NL, Kong JD, Wu J. Is monkeypox a new, emerging sexually transmitted disease? A rapid review of the literature. *J Med Virol* 2023; **95**(1): e28145.

19. Branda F, Ceccarelli G, Ciccozzi M, Scarpa F. First cases of mpox Clade I outside of Africa: genetic insights on its evolution. *Infectious Diseases* 2024; **56**(11): 1003-5.
20. Bunge EM, Hoet B, Chen L, et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. *PLoS Negl Trop Dis* 2022; **16**(2): e0010141.
21. Cadmus S, Akinseye V, Besong M, et al. Dynamics of Mpox infection in Nigeria: a systematic review and meta-analysis. *Sci Rep* 2024; **14**(1): 7368.
22. Chadaga K, Prabhu S, Sampathila N, et al. Application of Artificial Intelligence Techniques for Monkeypox: A Systematic Review. *Diagnostics (Basel)* 2023; **13**(5).
23. Chatterjee S, Sharma AR, Bhattacharya M, Dhama K, Lee SS, Chakraborty C. Relooking the monkeypox virus during this present outbreak: epidemiology to therapeutics and vaccines. *Eur Rev Med Pharmacol Sci* 2022; **26**(16): 5991-6003.
24. Chaudhari S, Treffeisen L, Virk J, et al. The 2022 Monkeypox Epidemic and What Has Led to the Current State of the Disease in the US: A Systematic Review. *Cureus* 2023; **15**(1): e33515.
25. Chauhan RP, Fogel R, Limson J. Overview of Diagnostic Methods, Disease Prevalence and Transmission of Mpox (Formerly Monkeypox) in Humans and Animal Reservoirs. *Microorganisms* 2023; **11**(5).
26. Chenchula S, Ghanta MK, Amerneni KC, et al. A systematic review to identify novel clinical characteristics of monkeypox virus infection and therapeutic and preventive strategies to combat the virus. *Arch Virol* 2023; **168**(7): 195.
27. Cho W, Park S, Kim HJ, et al. Clinical characteristics and outcomes of patients with mpox during the 2022 mpox outbreak compared with those before the outbreak: A systematic review and meta-analysis. *Rev Med Virol* 2024; **34**(1): e2508.
28. D'Antonio F, Pagani G, Buca D, Khalil A. Monkeypox infection in pregnancy: a systematic review and metaanalysis. *Am J Obstet Gynecol MFM* 2023; **5**(1): 100747.
29. da Silva K, Granzotti RBG, César C, et al. Emerging Challenges of Mpox Transmission: An In-depth Scoping Review and Evidence Mapping on Breastfeeding Practices in South America. *Pediatr Infect Dis J* 2024; **43**(10): e341-e6.
30. Daitao Z, Haoyuan J, Yulan S, et al. Vital surveillances: Genetic features of 84 genomes of Monkeypox virus in recent circulation - Beijing municipality, China, 2023. *China CDC Weekly* 2023; **5**(41): 918-21.
31. Deb N, Roy P, Biswakarma A, et al. Neurological Manifestations of Coronavirus Disease 2019 and Mpox in Pediatric Patients and Their Management: A State-of-the-Art Systematic Review. *Pediatr Neurol* 2023; **146**: 65-78.
32. Derhab N. Human monkeypox virus: A systematic critical review during the pandemic peak. *Indian J Med Microbiol* 2024; **51**: 100704.
33. DeWitt ME, Polk C, Williamson J, et al. Global monkeypox case hospitalisation rates: A rapid systematic review and meta-analysis. *EClinicalMedicine* 2022; **54**: 101710.
34. Di Gennaro F, Veronese N, Marotta C, et al. Human Monkeypox: A Comprehensive Narrative Review and Analysis of the Public Health Implications. *Microorganisms* 2022; **10**(8).
35. Diatta K, Faye O, Sall AA, Faye M. Useful public health countermeasures to control the current multicountry outbreak of Monkeypox disease. *Front Public Health* 2022; **10**: 1060678.
36. Djuicy D, Sadeuh-Mba S, Bilounga C, et al. Concurrent clade I and clade II Monkeypox virus circulation, Cameroon, 1979–2022. *Emerging Infectious Disease Journal* 2024; **30**(3): 432.
37. Doshi RH, Alfonso VH, Morier D, et al. Monkeypox rash severity and animal exposures in the Democratic Republic of the Congo. *EcoHealth* 2020; **17**(1): 64-73.
38. Dou YM, Yuan H, Tian HW. Monkeypox virus: past and present. *World J Pediatr* 2023; **19**(3): 224-30.

39. Dsouza VS, Pattanshetty S, Raj R, Ds A, Gudi N, Brand H. Rapid review on monkeypox policies among the G20 nations: relevance to policy and practitioner. *F1000Res* 2022; **11**: 1360.
40. Du M, Sun H, Zhang S, et al. Global Epidemiological Features of Human Monkeypox Cases and Their Associations With Social-Economic Level and International Travel Arrivals: A Systematic Review and Ecological Study. *Int J Public Health* 2023; **68**: 1605426.
41. Du Z, Shao Z, Bai Y, et al. Reproduction number of monkeypox in the early stage of the 2022 multi-country outbreak. *Journal of Travel Medicine* 2022; **29**(8): taac099.
42. Dudani P, Sharma A, Tammineni MS, Gupta S. Monkeypox (Mpox): Evolution of Transmission and Comprehensive Review. *Indian J Dermatol* 2023; **68**(6): 647-56.
43. El Dine FB, Gebreal A, Samhoury D, et al. Ethical considerations during Mpox Outbreak: a scoping review. *BMC Med Ethics* 2024; **25**(1): 79.
44. Eslami A, Alimoghadam S, Khoshravesh S, Shirani M, Alimoghadam R, Alavi Darazam I. Mpox vaccination and treatment: a systematic review. *J Chemother* 2024; **36**(2): 85-109.
45. Formenty P, Muntasir MO, Damon I, et al. Human monkeypox outbreak caused by novel virus belonging to Congo Basin clade, Sudan, 2005. *Emerging Infectious Disease Journal* 2010; **16**(10): 1539-45.
46. Forni D, Molteni C, Cagliani R, Sironi M. Geographic structuring and divergence time frame of Monkeypox virus in the endemic region. *The Journal of Infectious Diseases* 2022; **227**(6): 742-51.
47. Fox T, Gould S, Princy N, Rowland T, Lutje V, Kuehn R. Therapeutics for treating mpox in humans. *Cochrane Database of Systematic Reviews* 2023; (3).
48. Gaeta F, De Caro F, Franci G, Pagliano P, Vajro P, Mandato C. Monkeypox Infection 2022: An Updated Narrative Review Focusing on the Neonatal and Pediatric Population. *Children (Basel)* 2022; **9**(12).
49. Gandhi AP, Gupta PC, Padhi BK, et al. Ophthalmic Manifestations of the Monkeypox Virus: A Systematic Review and Meta-Analysis. *Pathogens* 2023; **12**(3).
50. Gandhi AP, Padhi BK, Sandeep M, et al. Monkeypox Patients Living with HIV: A Systematic Review and Meta-Analysis of Geographic and Temporal Variations. *Epidemiologia (Basel)* 2023; **4**(3): 352-69.
51. Garba-Ouangole S, Bournier J, Mbrenge F, et al. Laboratory Diagnosis of Mpox, Central African Republic, 2016–2022. *Emerging Infectious Diseases* 2023; **29**(9): 1846.
52. Ghazy RM, Elrewany E, Gebreal A, et al. Systematic Review on the Efficacy, Effectiveness, Safety, and Immunogenicity of Monkeypox Vaccine. *Vaccines (Basel)* 2023; **11**(11).
53. Ghazy RM, Hammad EM, Hall MA, et al. How can imported monkeypox break the borders? A rapid systematic review. *Comp Immunol Microbiol Infect Dis* 2023; **92**: 101923.
54. Gonah L, Nomatshila SC. Social and Behavioural Change Communication Challenges, Opportunities and Lessons from Past Public Health Emergencies and Disease Outbreaks: A Scoping Review. *Annals of Global Health* 2024; **90**(1): 62.
55. Gong L, Chen X, Wang Y, Liang J, Liu X, Wang Y. Rapid, sensitive, and highly specific detection of monkeypox virus by CRISPR-based diagnostic platform. *Frontiers in Public Health* 2023; **11**.
56. Goyal L, Ajmera K, Pandit R, Pandit T. Prevention and Treatment of Monkeypox: A Step-by-Step Guide for Healthcare Professionals and General Population. *Cureus* 2022; **14**(8): e28230.
57. Hallo-Carrasco A, Hunt CL, Prusinski CC, et al. Pain Associated With Monkeypox Virus: A Rapid Review. *Cureus* 2023; **15**(2): e34697.
58. Han Y, Wang X, Li X, Zhong Z. The willingness of healthcare workers to be vaccinated against monkeypox and their knowledge about monkeypox: A systematic review and meta-analysis. *Heliyon* 2024; **10**(15): e35196.

59. Hatami H, Jamshidi P, Arbabi M, et al. Demographic, Epidemiologic, and Clinical Characteristics of Human Monkeypox Disease Pre- and Post-2022 Outbreaks: A Systematic Review and Meta-Analysis. *Biomedicines* 2023; **11**(3).
60. He G-Y, Tay S-Y, Tan B-W, Tan E-K. Monkeypox infections: seizures and encephalitis. Oxford University Press; 2023. p. 267-70.
61. Hemati S, Mohammadi-Moghadam F. A systematic review on environmental perspectives of monkeypox virus. *Rev Environ Health* 2024; **39**(2): 363-70.
62. Huang P, Huang Z, Liu M, et al. A visual assay panel for the identification of monkeypox virus DNA belonging to the clades I and II. *Virologica Sinica* 2023; **38**(4): 635-8.
63. Islam MR, Hossain MJ, Roy A, et al. Repositioning potentials of smallpox vaccines and antiviral agents in monkeypox outbreak: A rapid review on comparative benefits and risks. *Health science reports* 2022; **5**(5): e798.
64. Issa AW, Alkhofash NF, Gopinath D, Varma SR. Oral Manifestations in Monkeypox: A Scoping Review on Implications for Oral Health. *Dent J (Basel)* 2023; **11**(5).
65. Jahromi AS, Jokar M, Sharifi N, Kashkooli S, Rahmanian K, Rahmanian V. Global knowledge and attitudes towards mpox (monkeypox) among healthcare workers: a systematic review and meta-analysis. *Int Health* 2024; **16**(5): 487-98.
66. Jaiswal V, Nain P, Mukherjee D, et al. Symptomatology, prognosis, and clinical findings of Monkeypox infected patients during COVID-19 era: A systematic-review. *Immun Inflamm Dis* 2022; **10**(11): e722.
67. Jaiswal V, Sultana Q, Lahori S, et al. Monkeypox-Induced Myocarditis: A Systematic Review. *Curr Probl Cardiol* 2023; **48**(5): 101611.
68. Jaleel A, Farid G, Irfan H, Mahmood K, Baig S. A Systematic Review on the Mental Health Status of Patients Infected With Monkeypox Virus. *Soa Chongsanyon Chongsin Uihak* 2024; **35**(2): 107-18.
69. Javelle E, Ficko C, Savini H, et al. Monkeypox clinical disease: Literature review and a tool proposal for the monitoring of cases and contacts. *Travel Med Infect Dis* 2023; **52**: 102559.
70. Joseph B, Anil S. Oral lesions in human monkeypox disease and their management-a scoping review. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2023; **135**(4): 510-7.
71. Kamaratos-Sevdalis N, Kourampi I, Ozturk NB, Mavromanoli AC, Tsagkaris C. Mpox and Surgery: Protocols, Precautions, and Recommendations. *Microorganisms* 2024; **12**(9).
72. Kandeel M. Meta-Analysis of Demographic Disparities in Monkeypox Infections among Diverse Populations. *New Microbiol* 2024; **46**(4): 322-31.
73. Khan SA, Parajuli SB, Rauniyar VK. Neurological manifestations of an emerging zoonosis-Human monkeypox virus: A systematic review. *Medicine (Baltimore)* 2023; **102**(35): e34664.
74. Kibungu EM, Vakaniaki EH, Kinganda-Lusamaki E, et al. Clade I-associated mpox cases associated with sexual contact, the Democratic Republic of the Congo. *Emerging Infectious Diseases* 2024; **30**(1): 172.
75. Kim H, Kwon R, Lee H, et al. Viral load dynamics and shedding kinetics of mpox infection: a systematic review and meta-analysis. *J Travel Med* 2023; **30**(5).
76. Kinganda-Lusamaki E, Amuri-Aziza A, Fernandez-Nuñez N, et al. Clade I mpox virus genomic diversity in the Democratic Republic of the Congo 2018-2024: Predominance of zoonotic transmission. *Cell* 2024.
77. Kipkorir V, Dhali A, Srichawla B, et al. The re-emerging monkeypox disease. *Trop Med Int Health* 2022; **27**(11): 961-9.
78. Kuehn R, Fox T, Guyatt G, Lutje V, Gould S. Infection prevention and control measures to reduce the transmission of mpox: A systematic review. *PLOS Glob Public Health* 2024; **4**(1): e0002731.
79. Kumar R, Singh S, Singh SK. A Systematic Review of 5110 Cases of Monkeypox: What Has Changed Between 1970 and 2022? *Cureus* 2022; **14**(10): e30841.

80. Kumar S, Rahul K, Gupta AK, et al. As the World Struggles With the COVID-19 Pandemic, Another Emergency Threat Arrives on the Horizon, the Monkeypox: A Systematic Review. *Cureus* 2023; **15**(1): e33596.
81. Kuroda N, Shimizu T, Hirano D, Ishikane M, Kataoka Y. Lack of clinical evidence of antiviral therapy for human monkeypox: A scoping review. *J Infect Chemother* 2023; **29**(2): 228-31.
82. Lagerqvist N, Beser J, Bakonyi T, Gossner CM, Palm D. Diagnostic and surveillance testing capability for mpox in the EU/EEA, September 2024. *Euro Surveill* 2024; **29**(42).
83. Laiton-Donato K, Álvarez-Díaz DA, Franco-Muñoz C, et al. Monkeypox virus genome sequence from an imported human case in Colombia. *Biomédica* 2022; **42**: 541-5.
84. Lawrence A, Anejo-Okopi J, Adeseye B. The Feasibility of Elimination of Monkeypox Virus in Nigeria: A Systematic Review. *Cureus* 2024; **16**(6): e61867.
85. León-Figueroa DA, Barboza JJ, Garcia-Vasquez EA, et al. Epidemiological Situation of Monkeypox Transmission by Possible Sexual Contact: A Systematic Review. *Trop Med Infect Dis* 2022; **7**(10).
86. León-Figueroa DA, Barboza JJ, Saldaña-Cumpa HM, et al. Detection of Monkeypox Virus according to The Collection Site of Samples from Confirmed Cases: A Systematic Review. *Trop Med Infect Dis* 2022; **8**(1).
87. León-Figueroa DA, Barboza JJ, Siddiq A, Sah R, Valladares-Garrido MJ, Rodriguez-Morales AJ. Knowledge and attitude towards mpox: Systematic review and meta-analysis. *PLoS One* 2024; **19**(8): e0308478.
88. León-Figueroa DA, Barboza JJ, Valladares-Garrido MJ. Sources of information on monkeypox virus infection. A systematic review with meta-analysis. *BMC Public Health* 2024; **24**(1): 276.
89. León-Figueroa DA, Barboza JJ, Valladares-Garrido MJ, Sah R, Rodriguez-Morales AJ. Prevalence of intentions to receive monkeypox vaccine. A systematic review and meta-analysis. *BMC Public Health* 2024; **24**(1): 35.
90. Li P, Li J, Ayada I, et al. Clinical Features, Antiviral Treatment, and Patient Outcomes: A Systematic Review and Comparative Analysis of the Previous and the 2022 Mpox Outbreaks. *J Infect Dis* 2023; **228**(4): 391-401.
91. Li T, Li Z, Xia Y, Long J, Qi L. Mpox reinfection: A rapid systematic review of case reports. *Infect Med (Beijing)* 2024; **3**(1): 100096.
92. Li Y, Hou J, Sun Z, et al. Monkeypox virus 2022, gene heterogeneity and protein polymorphism. *Signal Transduction and Target Therapy* 2023; **8**(1): 278.
93. Liu H, Wang W, Zhang Y, et al. Global perspectives on smallpox vaccine against monkeypox: a comprehensive meta-analysis and systematic review of effectiveness, protection, safety and cross-immunogenicity. *Emerg Microbes Infect* 2024; **13**(1): 2387442.
94. Liu J, Liu S, Yu S, et al. Willingness to receive mpox vaccine among men who have sex with men: a systematic review and meta-analysis. *BMC Public Health* 2024; **24**(1): 1878.
95. Liu Q, Fu L, Wang B, et al. Clinical Characteristics of Human Mpox (Monkeypox) in 2022: A Systematic Review and Meta-Analysis. *Pathogens* 2023; **12**(1).
96. Lounis M, Riad A. Monkeypox (MPOX)-Related Knowledge and Vaccination Hesitancy in Non-Endemic Countries: Concise Literature Review. *Vaccines (Basel)* 2023; **11**(2).
97. Lulli LG, Baldassarre A, Mucci N, Arcangeli G. Prevention, Risk Exposure, and Knowledge of Monkeypox in Occupational Settings: A Scoping Review. *Trop Med Infect Dis* 2022; **7**(10).
98. Mahdi SS, Yaqoob R, Allana R, et al. Monkeypox resurgence and its implications for Dentistry - A scoping review. *Ig Sanita Pubbl* 2023; **80**(2): 49-59.
99. Malik S, Ahmad T, Ahsan O, Muhammad K, Waheed Y. Recent Developments in Mpox Prevention and Treatment Options. *Vaccines (Basel)* 2023; **11**(3).

100. Malik S, Ahmed A, Ahsan O, Muhammad K, Waheed Y. Monkeypox Virus: A Comprehensive Overview of Viral Pathology, Immune Response, and Antiviral Strategies. *Vaccines (Basel)* 2023; **11**(8).
101. Malone SM, Mitra AK, Onumah NA, et al. Safety and Efficacy of Post-Eradication Smallpox Vaccine as an Mpox Vaccine: A Systematic Review with Meta-Analysis. *Int J Environ Res Public Health* 2023; **20**(4).
102. Martins-Filho PR, Tanajura DM, Vecina-Neto G. Multi-country monkeypox outbreak: a quantitative evidence synthesis on clinical characteristics, potential transmission routes, and risk factors. *European Journal of Internal Medicine* 2023; **107**: 102-4.
103. Maru V, Ghaffar UB, Rawat A, et al. Clinical and Epidemiological Interventions for Monkeypox Management in Children: A Systematic Review. *Cureus* 2023; **15**(5): e38521.
104. Marziano V, Guzzetta G, Longini I, Merler S. Epidemiologic Quantities for Monkeypox Virus Clade I from Historical Data with Implications for Current Outbreaks, Democratic Republic of the Congo. *Emerg Infect Dis* 2024; **30**(10): 2042-6.
105. Masirika LM, Kumar A, Dutt M, et al. Complete genome sequencing, annotation, and mutational profiling of the novel clade I human Mpox virus, kamituga strain. *Journal of Infection in Developing Countries* 2024; **18**(4): 600-8.
106. Mason LMK, Betancur E, Riera-Montes M, Lienert F, Scheele S. MVA-BN vaccine effectiveness: A systematic review of real-world evidence in outbreak settings. *Vaccine* 2024; **42**(26): 126409.
107. Mbrennga F, Nakouné E, Malaka C, et al. Tecovirimat for Monkeypox in Central African Republic under Expanded Access. *N Engl J Med* 2022; **2022/12/01**.
108. Mektebi A, Elsaid M, Yadav T, et al. Mpox vaccine acceptance among healthcare workers: a systematic review and meta-analysis. *BMC Public Health* 2024; **24**(1): 4.
109. Moawad MH, Taha AM, Nguyen D, et al. Attitudes towards Receiving Monkeypox Vaccination: A Systematic Review and Meta-Analysis. *Vaccines (Basel)* 2023; **11**(12).
110. Molteni C, Forni D, Cagliani R, et al. Selective events at individual sites underlie the evolution of monkeypox virus clades. *Virus Evolution* 2023; **9**(1).
111. Mostafa HH, Wall G, Su S-C, et al. Multi-center evaluation of the Research Use Only NeuMoDx monkeypox virus (MPXV) fully automated real-time PCR assay. *Journal of Clinical Microbiology* 2024; **62**(5): e00028-24.
112. Musuka G, Moyo E, Tungwarara N, et al. A critical review of mpox outbreaks, risk factors, and prevention efforts in Africa: lessons learned and evolving practices. *IJID Reg* 2024; **12**: 100402.
113. Nagarajan P, Howlader A, Louis LRP, Rangarajulu K. Outbreaks of human monkeypox during the COVID-19 pandemic: a systematic review for healthcare professionals. *Iran J Microbiol* 2022; **14**(6): 778-91.
114. Nakoune E, Lampaert E, Ndjapou SG, et al. A nosocomial outbreak of human Monkeypox in the Central African Republic. *Open Forum Infectious Diseases* 2017; **4**(4).
115. Nave L, Margalit I, Tau N, et al. Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine-A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Vaccines (Basel)* 2023; **11**(9).
116. Núñez-Cortés R, Calatayud J, López-Gil JF, Koyanagi A, Casaña J, López-Bueno R. Risk profile and mode of transmission of Mpox: A rapid review and individual patient data meta-analysis of case studies. *Rev Med Virol* 2023; **33**(2): e2410.
117. Okoli GN, Van Caesele P, Askin N, Abou-Setta AM. Comparative evaluation of the clinical presentation and epidemiology of the 2022 and previous Mpox outbreaks: a rapid review and meta-analysis. *Infect Dis (Lond)* 2023; **55**(7): 490-508.
118. Okoli GN, Van Caesele P, Askin N, Abou-Setta AM. A global systematic evidence review with meta-analysis of the epidemiological characteristics of the 2022 Mpox outbreaks. *Infection* 2024; **52**(3): 901-21.

119. Ortiz-Saavedra B, León-Figueroa DA, Montes-Madariaga ES, et al. Antiviral Treatment against Monkeypox: A Scoping Review. *Trop Med Infect Dis* 2022; **7**(11).
120. Ortiz-Saavedra B, Montes-Madariaga ES, Cabanillas-Ramirez C, et al. Epidemiologic Situation of HIV and Monkeypox Coinfection: A Systematic Review. *Vaccines (Basel)* 2023; **11**(2).
121. Otieno JR, Ruis C, Onoja AB, et al. Global genomic surveillance of monkeypox virus. *Nature Medicine* 2024.
122. Pang Y, Cao D, Zhu X, et al. Safety and Efficacy of the Modified Vaccinia Ankara-Bavaria Nordic Vaccine Against Mpox in the Real World: Systematic Review and Meta-Analysis. *Viral Immunol* 2024; **37**(4): 216-9.
123. Paparini S, Whelan I, Mwendera C, et al. Prevention of sexual transmission of mpox: a systematic review and qualitative evidence synthesis of approaches. *Infect Dis (Lond)* 2024; **56**(8): 589-605.
124. Pesonel E, Hoffmann I, Guiraud L, et al. MOSAIC: A cohort study of human mpox virus disease. *Wellcome Open Res*; 2023.
125. Pinto P, Costa MA, Gonçalves MFM, Rodrigues AG, Lisboa C. Mpox Person-to-Person Transmission-Where Have We Got So Far? A Systematic Review. *Viruses* 2023; **15**(5).
126. Pischel L, Martini BA, Yu N, et al. Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis. *Vaccine* 2024.
127. Poland GA, Kennedy RB, Tosh PK. Prevention of monkeypox with vaccines: a rapid review. *Lancet Infect Dis* 2022; **22**(12): e349-e58.
128. Ponce L, Linton NM, Toh WH, et al. Incubation Period and Serial Interval of Mpox in 2022 Global Outbreak Compared with Historical Estimates. *Emerging Infectious Diseases* 2024; **30**(6): 1173.
129. Rahimi FS, Afaghi S, Tarki FE, et al. The historical epidemiology of human monkeypox: A review of evidence from the 1970 Emergence to the 2022 Outbreak. *The Tohoku Journal of Experimental Medicine* 2022; **258**(4): 243-55.
130. Rahmani E, Bayat Z, Farrokhi M, et al. Monkeypox: A Comprehensive Review of Virology, Epidemiology, Transmission, Diagnosis, Prevention, Treatment, and Artificial Intelligence Applications. *Arch Acad Emerg Med* 2024; **12**(1): e70.
131. Ramakrishnan R, Shenoy A, Madhavan R, Meyer D. Mpox gastrointestinal manifestations: a systematic review. *BMJ Open Gastroenterol* 2024; **11**(1).
132. Rani I, Goyal A, Shamim MA, et al. Prevalence of mpox viral DNA in cutaneous specimens of monkeypox-infected patients: a systematic review and meta-analysis. *Front Cell Infect Microbiol* 2023; **13**: 1179885.
133. Rani I, Satapathy P, Goyal A, et al. Viral Loads in Skin Samples of Patients with Monkeypox Virus Infection: A Systematic Review and Meta-Analysis. *Viruses* 2023; **15**(6).
134. Reda A, Abdelaal A, Brakat AM, et al. Monkeypox viral detection in semen specimens of confirmed cases: A systematic review and meta-analysis. *J Med Virol* 2023; **95**(1): e28250.
135. Reda A, Hemmeda L, Brakat AM, Sah R, El-Qushayri AE. The clinical manifestations and severity of the 2022 monkeypox outbreak among 4080 patients. *Travel Medicine and Infectious Disease* 2022; **50**: 102456.
136. Rojas-Carabali W, Cifuentes-González C, Agrawal R, de-la-Torre A. Spectrum of ophthalmic manifestations in monkeypox virus infection worldwide: Systematic review and meta-analysis. *Heliyon* 2023; **9**(8): e18561.
137. Sanchez Clemente N, Coles C, Paixao ES, et al. Paediatric, maternal, and congenital mpox: a systematic review and meta-analysis. *Lancet Glob Health* 2024; **12**(4): e572-e88.
138. Satapathy P, Khatib MN, Gaidhane S, et al. Multi-organ clinical manifestations of Mpox: an umbrella review of systematic reviews. *BMC Infect Dis* 2024; **24**(1): 992.
139. Satapathy P, Mohanty P, Manna S, et al. Potentially Asymptomatic Infection of Monkeypox Virus: A Systematic Review and Meta-Analysis. *Vaccines (Basel)* 2022; **10**(12).

140. Satapathy P, Shamim MA, Padhi BK, et al. Mpox virus infection in women and outbreak sex disparities: A Systematic Review and Meta-analysis. *Commun Med (Lond)* 2024; **4**(1): 188.
141. Sayad R, Siddiq A, Hashim A, Elsaedy AS. Can the current monkeypox affect the heart? A systematic review of case series and case report. *BMC Cardiovasc Disord* 2023; **23**(1): 328.
142. Schuele L, Masirika LM, Udahehuka JC, et al. Real-time PCR assay to detect the novel Clade Ib monkeypox virus, September 2023 to May 2024. *Eurosurveillance* 2024; **29**(32): 2400486.
143. Shah J, Saak TM, Desai AN, et al. Otolaryngologic manifestations among MPOX patients: A systematic review and meta-analysis. *Am J Otolaryngol* 2023; **44**(6): 103991.
144. Sham S, Sapna F, Anjali F, et al. The Changing Global Epidemiology of Re-emerging Human Monkeypox Virus Infection: A Systematic Review. *Cureus* 2023; **15**(9): e45123.
145. Shamim MA, Padhi BK, Satapathy P, et al. The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review. *Int J Infect Dis* 2023; **127**: 150-61.
146. Sharif N, Sharif N, Alzahrani KJ, et al. Molecular epidemiology, transmission and clinical features of 2022-mpox outbreak: A systematic review. *Health Sci Rep* 2023; **6**,20231005(10): e1603.
147. Sharma A, Prasad H, Kaeley N, Bondalapati A, Edara L, Kumar YA. Monkeypox epidemiology, clinical presentation, and transmission: a systematic review. *Int J Emerg Med* 2023; **16**(1): 20.
148. Sharma R, Chen KT. Emerging evidence on Monkeypox: resurgence, global burden, molecular insights, genomics and possible management. *Front Cell Infect Microbiol* 2023; **13**: 1134712.
149. Shin H, Rahmati M, Koyanagi A, et al. Comparison of clinical manifestations in mpox patients living with HIV versus without HIV: A systematic review and meta-analysis. *J Med Virol* 2023; **95**(4): e28713.
150. Simadibrata DM, Lesmana E, Pratama MIA, Annisa NG, Thenedi K, Simadibrata M. Gastrointestinal Symptoms of Monkeypox Infection: A systematic review and meta-analysis. *J Med Virol* 2023; **95**(4): e28709.
151. Su S, Jia M, Yu Y, et al. Integrated Network Analysis of Symptom Clusters Across Monkeypox Epidemics From 1970 to 2023: Systematic Review and Meta-Analysis. *JMIR Public Health Surveill* 2024; **10**: e49285.
152. Subissi L. Overview of clinical characteristics of various MPXV clades. Aligning Mpox Research Response with Outbreak Goals-Scientific Conference; 2024.
153. Sudarmaji N, Kifli N, Hermansyah A, Yeoh SF, Goh BH, Ming LC. Prevention and Treatment of Monkeypox: A Systematic Review of Preclinical Studies. *Viruses* 2022; **14**(11).
154. Sulaiman SK, Isma'il Tsiga-Ahmed F, Musa MS, Makama BT, Sulaiman AK, Abdulaziz TB. Global prevalence and correlates of mpox vaccine acceptance and uptake: a systematic review and meta-analysis. *Commun Med (Lond)* 2024; **4**(1): 136.
155. Sun Y-Q, Chen J-J, Liu M-C, et al. Mapping global zoonotic niche and interregional transmission risk of monkeypox: A retrospective observational study. *Globalization and Health* 2023; **19**(1): 58.
156. Taha AM, Elrosasy A, Mahmoud AM, et al. The effect of HIV and mpox co-infection on clinical outcomes: Systematic review and meta-analysis. *HIV Med* 2024; **25**(8): 897-909.
157. Taha AM, Mahmoud AM, Abouelmagd K, et al. Effectiveness of a single dose of JYNNEOS vaccine in real world: A systematic review and meta-analysis. *Health Sci Rep* 2024; **7**(9): e70069.
158. Tajudeen YA, Oladipo HJ, Muili AO, Ikebuaso JG. Monkeypox: A review of a zoonotic disease of global public health concern. *Health Promot Perspect* 2023; **13**(1): 1-9.
159. Tanashat M, Altobaishat O, Sharaf A, Hossam El Din Moawad M, Al-Jafari M, Nashwan AJ. Assessment of the knowledge, attitude, and perception of the world's population towards monkeypox and its vaccines: A systematic review and descriptive analysis of cross-sectional studies. *Vaccine X* 2024; **20**: 100527.

160. Titanji BK, Hazra A, Zucker J. Mpox Clinical Presentation, Diagnostic Approaches, and Treatment Strategies: A Review. *JAMA* 2024; **332**(19): 1652-62.
161. Ulloque-Badaracco JR, Alarcón-Braga EA, Hernandez-Bustamante EA, et al. Acceptance towards Monkeypox Vaccination: A Systematic Review and Meta-Analysis. *Pathogens* 2022; **11**(11).
162. Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, et al. Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo. *Nature Medicine* 2024; **30**(10): 2791-5.
163. Van Dijck C, Hoff NA, Mbala-Kingebeni P, et al. Emergence of mpox in the post-smallpox 2014: A narrative review on mpox epidemiology. *Clinical Microbiology and Infection* 2023; **29**(12): 1487-92.
164. Vandenbogaert M, Kwasiborski A, Gonofio E, et al. Nanopore sequencing of a monkeypox virus strain isolated from a pustular lesion in the Central African Republic. *Scientific Reports* 2022; **12**(1): 10768.
165. Wang S, Zhang F, Yuan Z, et al. Serial intervals and incubation periods of the monkeypox virus clades. *Journal of Travel Medicine* 2022; **29**(8): taac105.
166. Wawina-Bokalanga T, Sklenovska N, Vanmechelen B, et al. An accurate and rapid Real-time PCR approach for human Monkeypox virus diagnosis. *medRxiv* 2022: 2022.06.23.22276033.
167. Webb E, Rigby I, Michelen M, et al. Availability, scope and quality of monkeypox clinical management guidelines globally: a systematic review. *BMJ Glob Health* 2022; **7**(8).
168. Xu M, Liu C, Du Z, Bai Y, Wang Z, Gao C. Real-world effectiveness of monkeypox vaccines: a systematic review. *J Travel Med* 2023; **30**(5).
169. Yan X, Li Z, Cao C, et al. Characteristics, Influence, Prevention, and Control Measures of the Mpox Infodemic: Scoping Review of Infodemiology Studies. *J Med Internet Res* 2024; **26**: e54874.
170. Yinda CK, Koukouikila-Koussounda F, Mayengue PI, et al. Likely cross-border introductions of MPXV Clade I into the Republic of the Congo from the Democratic Republic of the Congo. *medRxiv* 2024: 2024.08.21.24312265.
171. Yinda CK, Koukouikila-Koussounda F, Mayengue PI, et al. Genetic sequencing analysis of monkeypox virus clade I in Republic of the Congo: a cross-sectional, descriptive study. *Lancet* 2024; **404**(10465): 1815-22.
172. Yon H, Shin H, Shin JI, et al. Clinical manifestations of human Mpox infection: A systematic review and meta-analysis. *Rev Med Virol* 2023; **33**(4): e2446.

Bhuiya AR, Demaio P, Ali A, Grewal E, Sivanesanathan T, Whitelaw H, Wang Q, Mansilla C, Loeb M, Wilson MG. Living evidence profile #6.13b: Best-available evidence related to the mpox outbreak, Hamilton: McMaster Health Forum 4 December 2024.

Citizen partner acknowledgement: We are thankful to our citizen partners Annie-Danielle Grenier and Marion Knutson for their contribution to the living evidence profile by providing feedback that was incorporated into the final report.

This living evidence profile was funded by Public Health Agency of Canada. The McMaster Health Forum receives both financial and in-kind support from McMaster University. The views expressed in the rapid evidence profile are the views of the authors and should not be taken to represent the views of Public Health Agency of Canada or McMaster University. The authors wish to thank staff members who appraised the evidence syntheses: Sivanesanathan T, Gou D, Chen N, Whyte M, Cheng S, Lee J, Beltran R, Khan S, Vanderhorst S, Saleh S, Alkhawaja S